Le Lézard
Classified in: Health
Subject: FVT

Sigilon Therapeutics to Present at Upcoming Scientific and Investor Conferences


CAMBRIDGE, Mass., Feb. 23, 2018 /PRNewswire/ -- Sigilon Therapeutics, a biopharmaceutical company that discovers and develops immune-privileged living therapeutic implants, today announced that the company will present at the following upcoming conferences. Presentation details are as follows:

National Hemophilia Foundation 14th Workshop on Novel Technologies and Gene Transfer for Hemophilia



Presentation:  

Implantation of Immune Protected Cell Factories Protected by AfibromerTM Technology for the Treatment of Hemophilias 

Presenter:    

 David Peritt, Ph.D., Chief Technology Officer  

Date:  

Saturday, Feb. 24, 2018  

Time:  

10:45 a.m. EST 

Location:      

Capitol Hyatt Regency, Washington, D.C. 

 

BioCentury 25th Annual Future Leaders in the Biotech Industry Conference



Presenter:   

Paul Wotton, Ph.D., Chief Executive Officer  

Date:              

Friday, March 23, 2018 

Time:               

1:30 p.m. EDT  

Location:          

Millennium Broadway Hotel & Conference Center, New York  

About Sigilon Therapeutics

Founded and created by Flagship Pioneering, Sigilon Therapeutics is a biopharmaceutical company that discovers and develops immune-privileged living therapeutic implants for the treatment of chronic diseases. Treatments based on Sigilon Therapeutics' Afibromertm technology platform include cell implants that act as responsive "living therapeutics," providing more natural control for diseases that are currently treated with intermittent injection or infusion. Initial areas of focus include hematologic, enzyme deficiency, endocrine and metabolic disorders. More natural control would restore health and free patients from the need for therapies that are disruptive to quality of life.

For more information please visit www.sigilon.com or follow on Twitter at https://twitter.com/Sigilon_Inc.

SOURCE Sigilon Therapeutics


These press releases may also interest you

at 00:25
Shanghai Junshi Biosciences Co., Ltd ("Junshi Biosciences," HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced its financial...

28 mar 2024
The report titled "Central Lab Market by Service Type (Anatomic Pathology/Histology, Biomarker Services, Genetic Services), Phase (Phase 1, Phase 2, Phase 3), Therapeutic Area, End-use - Global Forecast 2024-2030" is now available on...

28 mar 2024
The report titled "Personalized Nutrition Market by Measurement Type (Active Measurement, Standard Measurement), Application (Indication-based, Standard Supplements), Distribution Channel, End-Use - Global Forecast 2024-2030" is now available on...

28 mar 2024
The report titled "Carbon Dioxide Incubator Market by Product (Air Jacketed CO2 Incubators, Direct Heat CO2 Incubators, Water Jacketed CO2 Incubators), Capacity (100-200 Litre, Above 200 Litre, Below 100 Litre), Application, End User - Global...

28 mar 2024
The "Global Clinical In Vitro Diagnostic Medical Laboratory Services Market: Strategy & Trends with Volume & Price Forecasts by Chemistry, Hematology, Microbiology, Pathology, Covid-19, and Molecular Dx by Country. Updated with Impact of COVID-19"...

28 mar 2024
The "Molecular Diagnostics at the Point of Care. By Application, Technology, Place, Product and by Country. With Executive Guides and Customization 2023 - 2027 " report has been added to  ResearchAndMarkets.com's offering. Infectious disease Dx is...



News published on and distributed by: